Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous Urticaria
28 mai 2024 07h02 HE
|
Allakos Inc.
– Top-line Phase 1 CSU results expected at year end 2024 – SAN CARLOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK006 for the...
Allakos Provides Business Update and Reports First Quarter 2024 Financial Results
09 mai 2024 16h02 HE
|
Allakos Inc.
SAN CARLOS, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and...
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
14 mars 2024 16h02 HE
|
Allakos Inc.
SAN CARLOS, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and...
Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024
26 févr. 2024 07h02 HE
|
Allakos Inc.
– Atopic dermatitis and prurigo nodularis skin lesions show evidence of MRGPRX2 mast cell activation and activated macrophages – – AK006 inhibited mast cell activation and reduced mast cell numbers...
Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition
12 févr. 2024 07h02 HE
|
Allakos Inc.
– Data provide insights on the signaling pathways involved with AK006 mast cell inhibition –– AK006 has a distinct mechanism of action that leads to broad inhibitory effects on mast cells – SAN...
Allakos Announces a Restructuring to Focus on Development of AK006
16 janv. 2024 07h02 HE
|
Allakos Inc.
Existing cash to fund planned ongoing operations into mid-2026AK006 is being tested in a comprehensive Phase 1 clinical program, including: ongoing single and multiple ascending dose trial in healthy...
Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints
16 janv. 2024 07h00 HE
|
Allakos Inc.
– Allakos plans not to pursue further development of lirentelimab; will focus on AK006 clinical development and additional preclinical programs – – Management to host conference call and webcast...
Allakos Provides Business Update and Reports Third Quarter 2023 Financial Results
13 nov. 2023 16h02 HE
|
Allakos Inc.
SAN CARLOS, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and...
Allakos Appoints Neil Graham to its Board of Directors
30 août 2023 16h05 HE
|
Allakos Inc.
SAN CARLOS, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on...
Allakos Provides Business Update and Reports Second Quarter 2023 Financial Results
09 août 2023 16h02 HE
|
Allakos Inc.
SAN CARLOS, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and...